Achillion has the potential to deliver the promise of complement-based therapeutics for a wide variety of diseases.Learn More
Achillion combines great science, a growing commercial capability, and a keen understanding of patient needs.Learn More
Achillion employs a highly-disciplined, scientifically rigorous, patient-focused approach across the continuum from drug discovery to patient care.Learn More
Factor D is a trigger point for complement activity and novel science at Achillion led to the discovery of Factor D inhibition.Learn More
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company seeking to leverage its strengths across the continuum from drug discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue best-in-class therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement factor D inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases.
Factor D provides a critical control point for complement activation. Small-molecule inhibitors of factor D may, therefore, be useful against a broad range of complement-mediated diseases.